Press Releases
Press Releases
Biogen SB5 accepted for review by European Medicines Agency
The Marketing Authorization Application (MAA) for SB5, an adalimumab biosimilar candidate referencing Humira®1, has been accepted for review by the EMA. The MAA for SB5 is the third anti-TNF biosimilar candidate to be submitted to the EMA by Samsung...
Press Releases
Abbott laboratories says U.S. FDA approves tecnis symfony intraocular lenses
Approval includes toric version of symfony iol for people with astigmatism lenses provide high-quality continuous vision so patients can see clearly at near, intermediate and far-away distances, and points in between, while wearing glasses less ...
Press Releases
Regeneron and Sanofi announce approval of praluent (alirocumab) in Japan
Sanofi and Regeneron Pharmaceuticals, Inc. announced that the Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Praluent® (alirocumab) for the treatment of uncontrolled low-density lipoprotein (LDL) cholesterol, in certain adult patients with...
Press Releases
Boehringer Ingelheim and University of Dundee collaborate to develop new class of medicines
Collaboration aims to develop PROteolysis TArgeting Chimeric molecules (PROTACs) – a new therapeutic modality that is able to degrade proteins playing a central role in disease processes PROTACs and their new mechanism of action are expected to open...
Press Releases
Health Canada approves Abbott’s Absorb Bioresorbable Stent
Revolutionary Device Made Of Naturally Dissolving Material, Similar To Dissolving Sutures Treats Coronary Artery Disease Like A Metallic Stent, But Then Disappears After The Artery Is Healed, Leaving No Metal Behind To Restrict Natural Vessel Motion....
Press Releases
Dailies Total1 Multifocal contact lenses launched for presbyopia- Alcon
Alcon, the global leader in eye care and a division of Novartis, introduces Dailies Total1 Multifocal contact lenses for people with presbyopia. This innovative multifocal lens provides both seamless distant, intermediate and near vision, and the outstanding comfort of...
Press Releases
U.S. FDA Grants Priority Review to Janssen’s New Drug Application for Chewable Mebendazole Tablets
Janssen Pharmaceuticals, Inc announced that the U.S. FDA has granted Priority Review designation for the NDA for a 500mg chewable tablet formulation of mebendazole. If approved, the chewable mebendazole tablet will provide a treatment and prevention alternative for adults...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
